Prostate Cancer Clinical Trial

ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Summary

A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced Solid Tumor with known PSMA Who Failed Prior Standard Therapies

View Full Description

Full Description

This is a first-in-human, Phase 1, multicenter, open-label study to evaluate the safety, PK, PDy, and preliminary anti-tumor activity of ARX517 in adult subjects with mCRPC with serum testosterone level < 50 ng/dL at screening who are resistant or refractory to standard therapies. Phase 1a (dose-escalation) and Phase 1b (dose-expansion) stages will identify the MTD and/or RDDs.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Male subjects ≥ 18 years at the first time of providing written informed consent.
Histologically confirmed prostate adenocarcinoma.
Documented metastatic disease and evidence of disease progression
Castration-resistant prostate cancer defined as surgical or medical castration with serum testosterone levels of ≤ 50 ng/dL (1.73 nM) at Screening. For patients who have not undergone an orchiectomy, must be undergoing treatment with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist and must agree to continue such therapy while on study treatment.

Prior receipt of the following for metastatic prostate cancer:

at least two lines of treatment
at least two Food and Drug Administration (FDA)-approved therapies with at least one being a second-generation androgen receptor signaling inhibitor (e.g., abiraterone, darolutamide, apalutamide, or enzalutamide).
Adequate blood counts

Key Exclusion Criteria:

Use of chronic systemic glucocorticoids equivalent to > 10 mg prednisone daily. Note: short-term administration of systemic corticosteroids > 10 mg prednisone equivalent (e.g., for allergic reactions or management of immune- or infusion-related AEs) is allowed.
Symptomatic and/or untreated central nervous system (CNS) metastases. Patients with asymptomatic, untreated CNS metastases are eligible provided they have been clinically stable (neurologically stable and not requiring steroids for at least 28 days prior to enrollment).
History of any invasive malignancy (other than primary) within the previous 2 years prior to the enrollment date that requires active therapy or is at high risk of recurrence in the opinion of the investigator.
Marked baseline prolongation of QT/QT interval corrected for heart rate (QTc), e.g., a triplicate-average QTc interval > 480 milliseconds (CTCAE Grade 2) using Fridericia's QT correction formula at any time within 28 days before enrollment, ongoing history of CTCAE Grade ≥2 QTc at enrollment, or anticipated need to perform repeat ECG evaluations to satisfy re-treatment criteria.
Prior history of interstitial lung disease, pneumonitis, or other clinically significant lung disease within 12 months prior to enrollment date,
Clinically significant ocular findings by a qualified ophthalmologist or optometrist including active ocular infections or chronic corneal disorders unless approved by the Medical Monitor.
Peripheral neuropathy Grade ≥ 2 within 28 days prior to enrollment.

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

262

Study ID:

NCT04662580

Recruitment Status:

Recruiting

Sponsor:

Ambrx, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

University of California Los Angeles School of Medicine
Los Angeles California, 90095, United States
UCSF
San Francisco California, 94143, United States
The Winship Cancer Institute of Emory University
Atlanta Georgia, 30322, United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis Indiana, 46202, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor Michigan, 48109, United States
Washington University School of Medicine
Saint Louis Missouri, 63110, United States
Urology Cancer Center, XCancer Research Network
Omaha Nebraska, 68130, United States
Weill Cornell Medical College
New York New York, 10065, United States
University of Washington
Seattle Washington, 98195, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

262

Study ID:

NCT04662580

Recruitment Status:

Recruiting

Sponsor:


Ambrx, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.